As of November 7, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Maze Therapeutics, Inc. The largest reported stake is Third Rock Ventures IV, L.P.'s, at 9.3%. 13 filings are on record since August 14, 2025 (Schedule 13G/A, February 13, 2026).
Sell to companies like Maze Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Paradigm BioCapital Advisors LP · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: BlackRock, Inc. · Sole voting: 2,922,889 · Shared voting: 0 · Sole dispositive: 2,978,114 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-29
- · Holder: Janus Henderson Group Plc · Percent: 5.8% · SCHEDULE 13G/A
- · Holder: Paradigm BioCapital Advisors LP · Percent: 6.1% · SCHEDULE 13G
- · Holder: Third Rock Ventures IV, L.P. · Percent: 9.3% · SCHEDULE 13G/A
Maze Therapeutics, Inc. has 13 Schedule 13D or 13G filings on record since 2025-08-14. 5 holders' latest filing reports 5% or more of common stock, $0.001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Third Rock Ventures IV, L.P. | 9.3% | 4,473,958 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 |
| Deep Track Capital, LP | 9.02% | 3,948,910 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Frazier Life Sciences Public Fund, L.P. | 9% | 4,342,266 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 |
| Janus Henderson Group Plc | 5.8% | 2,858,876 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| BlackRock, Inc. | 5.4% | 2,978,114 | SCHEDULE 13G, 2026-07-29 | 2026-06-30 |
| Matrix Capital Management Company, LP | 3.5% | 1,653,684 | SCHEDULE 13G/A, 2025-11-13 | 2025-09-30 |
| Alphabet Holdings LLC | 2.9% | 1,388,583 | SCHEDULE 13G/A, 2026-02-06 | 2025-12-31 |
| 1.4% | 608,948 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 | |
| Paradigm BioCapital Advisors LP | 0% | 0 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
Holding shares or following this stake? See who's behind Maze Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Maze Therapeutics, Inc. and the records around it.
Maze Therapeutics, Inc. elsewhere on the record
- Leadership changes Aug 2026
- IPO filing Oct 2025
- Who owns it
Companies that share a holder
- Third Rock Ventures IV, L.P. also filed stake reports on 1 other company: Tango Therapeutics, Inc. (Feb 2026)
- Foresite Capital Fund IV, L.P. also filed stake reports on 2 other companies: Lyell Immunopharma, Inc. (Aug 2026), Eikon Therapeutics, Inc. (Feb 2026)
- GV 2019, L.P. also filed stake reports on 2 other companies: Ethos Technologies Inc. (Nov 2026), Prime Medicine, Inc. (Nov 2025)
Watch Maze Therapeutics, Inc.
Get an email when Maze Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Maze Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Maze Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Maze Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
20 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 2,922,889 | 0 | 2,978,114 | 0 | SCHEDULE 13G, 2026-07-29 |
| Paradigm BioCapital Advisors LP | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Paradigm BioCapital Advisors GP LLC | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Senai Asefaw, M.D. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Paradigm BioCapital International Fund Ltd. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Maze Therapeutics, Inc. by CUSIP 578784100 and gives its principal executive office as 171 Oyster Point Blvd., Suite 300, South San Francisco, CA 94080 (SCHEDULE 13G/A, 2026-08-14).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Deep Track Capital, LP | 9.02% | SCHEDULE 13G/A |
| 2025-08-14 | Janus Henderson Group Plc | 6% | SCHEDULE 13G/A |
| 2025-08-14 | Frazier Life Sciences Public Fund, L.P. | 7.7% | SCHEDULE 13G/A |
| 2025-11-13 | Matrix Capital Management Company, LP | 3.5% | SCHEDULE 13G/A |
| 2025-11-14 | James Tananbaum | 1.4% | SCHEDULE 13G/A |
| 2025-11-14 | Janus Henderson Group Plc | 7.3% | SCHEDULE 13G/A |
| 2026-02-06 | Alphabet Holdings LLC | 2.9% | SCHEDULE 13G/A |
| 2026-02-13 | Third Rock Ventures IV, L.P. | 9.3% | SCHEDULE 13G/A |
| 2026-02-13 | Frazier Life Sciences Public Fund, L.P. | 9% | SCHEDULE 13G/A |
| 2026-04-01 | Paradigm BioCapital Advisors LP | 6.1% | SCHEDULE 13G |
| 2026-05-15 | Janus Henderson Group Plc | 5.8% | SCHEDULE 13G/A |
| 2026-07-29 | BlackRock, Inc. | 5.4% | SCHEDULE 13G |
| 2026-08-14 | Paradigm BioCapital Advisors LP | 0% | SCHEDULE 13G/A |
Questions about who owns Maze Therapeutics, Inc.
Who owns Maze Therapeutics, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Maze Therapeutics, Inc.: Third Rock Ventures IV, L.P. (9.3%, Schedule 13G/A, filed 2026-02-13), Deep Track Capital, LP (9.02%, Schedule 13G/A, filed 2025-08-14), Frazier Life Sciences Public Fund, L.P. (9%, Schedule 13G/A, filed 2026-02-13), Janus Henderson Group Plc (5.8%, Schedule 13G/A, filed 2026-05-15) and BlackRock, Inc. (5.4%, Schedule 13G, filed 2026-07-29).
Who are the largest shareholders of Maze Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Maze Therapeutics, Inc. on this page are Third Rock Ventures IV, L.P. (9.3%), Deep Track Capital, LP (9.02%) and Frazier Life Sciences Public Fund, L.P. (9%).
When did Third Rock Ventures IV, L.P. buy into Maze Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Third Rock Ventures IV, L.P. on this page is the Schedule 13G/A, filed 2026-02-13, reporting 9.3%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 13 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Maze Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 17, 2026 | Leadership change: Paula A. Johnson appointed, Director, and 1 more | — | Leadership changes | Source |
| May 22, 2026 | Leadership change: Amy Bachrodt departs, Senior Vice President, Finance | — | Leadership changes | Source |
| October 17, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
| January 31, 2025 | IPO filing, Form 424B4 | $16 a share | IPO filings | Source |
| January 30, 2025 | IPO filing, Form S-1/A | $15 to $17 a share | IPO filings | Source |
| January 27, 2025 | IPO filing, Form S-1/A | $15 to $17 a share | IPO filings | Source |
| January 7, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
Tools for this story
Each opens in a new tab, filled in for Maze Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.